re: PRs' issued .. not sure if there is a protocol .. we know pubcos have to file an 8K specific to events considered material in nature .. but of course what would be
material to a baby bio .. wouldn't necessarily be material for BP ..
like i'm sure a few others did .. i went back to see who noted what when
this is from the private company BDD Pharma
BDD Pharma Secures License Agreement with Top Pharma Company for Timed-release OralogiK™ Technology
BDD Pharma Logo (PRNewsfoto/BDD Pharma)
NEWS PROVIDED BY
BDD Pharma
May 30, 2018, 08:30 ET
GLASGOW, Scotland, May 30, 2018 /PRNewswire/ --
BDD Pharma today announced that it has signed an agreement to license OralogiK™, its timed drug delivery technology, to Novartis Pharma AG for the development of a new product containing an undisclosed compound. The agreement includes an upfront payment, milestones and future royalties.
https://www.prnewswire.com/news-releases/bdd-...44281.html
the public company noted in the deal above (Novartis) .. did not release a PR
Novartis did issue a PR on 5.30.18 .. but it pertained to another matter entirely
Media Release / May 30, 2018
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
Read More
https://www.novartis.com/news/news-archive?ty...mp;page=15
then i went to Innovation Pharma's website .. to see the dates of the PRs (and
we all come at this from varying perspectives) to see the 2019 PRs that imo
contain the most *clues* .. those are in bold .. btw i am not saying the other
PRs aren't of value or important .. but i'm convinced that NR sourced *something*
in mid to late February 2019 .. that changed out NRs' pattern of behavior re: IPIX
effective March 1 to May 1 .. which was then *adjusted* for NRs' set up (orchestrated run)
on IPIX in May .. NRs' pattern was then *adjusted* again (imo now parallels March's pattern)
and perhaps just me .. but imo NR is *anticipating* news (and has been for a
few weeks now) .. coincidence or not .. this is the longest Innovation Pharma
has gone without a PR issued in 2019 ( 6.6.19 to 7.14.19 is 5 weeks and counting )
June 6, 2019
INNOVATION PHARMACEUTICALS SIGNS AGREEMENT FOR ADVANCED ORAL TABLET TECHNOLOGY IN TREATING INFLAMMATORY BOWEL DISEASE
May 29, 2019
INNOVATION PHARMACEUTICALS TO ATTEND 2019 BIO INTERNATIONAL CONVENTION, JUNE 3-6
May 21, 2019
INNOVATION PHARMACEUTICALS AT DIGESTIVE DISEASE WEEK CONFERENCE
May 16, 2019
INNOVATION PHARMACEUTICALS ANNOUNCES NON-BINDING TERM SHEET SIGNED WITH GLOBAL PHARMACEUTICAL COMPANY TO DEVELOP AND COMMERCIALIZE BRILACIDIN FOR ULCERATIVE PROCTITIS/PROCTOSIGMOIDITIS
May 1, 2019
INNOVATION PHARMACEUTICALS RECEIVES FDA END-OF-PHASE 2 MEETING MINUTES
April 23, 2019
INNOVATION PHARMACEUTICALS - JAMA ARTICLE REINFORCES NEED FOR NOVEL ORAL MUCOSITIS TREATMENTS IN SUPPORTIVE CANCER CARE
April 16, 2019
INNOVATION PHARMACEUTICALS REPORTS P53 DRUG CANDIDATE THERAPEUTIC POTENTIAL FURTHER SUPPORTED BY ACADEMIC RESEARCH IN LEUKEMIAS AND IN COMBINATION WITH CANCER IMMUNOTHERAPIES
April 9, 2019
INNOVATION PHARMACEUTICALS REPORTS ENHANCEMENTS IN MANUFACTURE OF BRILACIDIN PHASE 3 DRUG SUPPLY
March 28, 2019
INNOVATION PHARMACEUTICALS EUROPEAN SUBSIDIARY, IPIX PHARMA LTD., GRANTED MEETING WITH EUROPEAN MEDICINES AGENCY (EMA) TO DISCUSS INTERNATIONAL PHASE 3 BRILACIDIN ORAL MUCOSITIS PROGRAM
March 14, 2019
INNOVATION PHARMACEUTICALS REQUESTING EUROPEAN MEDICINES AGENCY (EMA) INPUT FOR INTERNATIONAL PHASE 3 BRILACIDIN ORAL MUCOSITIS PROGRAM
February 26, 2019
INNOVATION PHARMACEUTICALS FORMS IRISH SUBSIDIARY TO FACILITATE INTERNATIONAL DEVELOPMENT OF CLINICAL PIPELINE
February 19, 2019
INNOVATION PHARMACEUTICALS RECEIVES NEW PATENT FOR COMPOUNDS FOR USE IN TREATMENT OF ORAL MUCOSITIS
February 11, 2019
INNOVATION PHARMACEUTICALS FILES FORM 10-Q QUARTERLY REPORT
January 31, 2019
INNOVATION PHARMACEUTICALS ESTABLISHING EUROPEAN SUBSIDIARY; CEO INCREASES EQUITY STAKE IN IPIX
January 22, 2019
INNOVATION PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT PLANS FOR ORAL BRILACIDIN FOR INFLAMMATORY BOWEL DISEASE
January 14, 2019
INNOVATION PHARMACEUTICALS COMPLETES GASTRIC FLUID TESTING OF BRILACIDIN SUPPORTING DEVELOPMENT OF AN ORAL DOSAGE FORM TO TREAT INFLAMMATORY BOWEL DISEASE
January 8, 2019
PUBLISHED STUDIES CONFIRM CISPLATIN REMAINS PREFERRED CHEMOTHERAPY COMPONENT IN HEAD AND NECK CANCER TREATMENT
January 2, 2019
INNOVATION PHARMACEUTICALS RECEIVES NEW BRILACIDIN PATENT, FURTHER EXPANDING INTELLECTUAL PROPERTY ESTATE
http://www.ipharminc.com/press-release
4kids
material to a baby bio .. wouldn't necessarily be material for BP ..
like i'm sure a few others did .. i went back to see who noted what when
this is from the private company BDD Pharma
BDD Pharma Secures License Agreement with Top Pharma Company for Timed-release OralogiK™ Technology
BDD Pharma Logo (PRNewsfoto/BDD Pharma)
NEWS PROVIDED BY
BDD Pharma
May 30, 2018, 08:30 ET
GLASGOW, Scotland, May 30, 2018 /PRNewswire/ --
BDD Pharma today announced that it has signed an agreement to license OralogiK™, its timed drug delivery technology, to Novartis Pharma AG for the development of a new product containing an undisclosed compound. The agreement includes an upfront payment, milestones and future royalties.
https://www.prnewswire.com/news-releases/bdd-...44281.html
the public company noted in the deal above (Novartis) .. did not release a PR
Novartis did issue a PR on 5.30.18 .. but it pertained to another matter entirely
Media Release / May 30, 2018
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
Read More
https://www.novartis.com/news/news-archive?ty...mp;page=15
then i went to Innovation Pharma's website .. to see the dates of the PRs (and
we all come at this from varying perspectives) to see the 2019 PRs that imo
contain the most *clues* .. those are in bold .. btw i am not saying the other
PRs aren't of value or important .. but i'm convinced that NR sourced *something*
in mid to late February 2019 .. that changed out NRs' pattern of behavior re: IPIX
effective March 1 to May 1 .. which was then *adjusted* for NRs' set up (orchestrated run)
on IPIX in May .. NRs' pattern was then *adjusted* again (imo now parallels March's pattern)
and perhaps just me .. but imo NR is *anticipating* news (and has been for a
few weeks now) .. coincidence or not .. this is the longest Innovation Pharma
has gone without a PR issued in 2019 ( 6.6.19 to 7.14.19 is 5 weeks and counting )
June 6, 2019
INNOVATION PHARMACEUTICALS SIGNS AGREEMENT FOR ADVANCED ORAL TABLET TECHNOLOGY IN TREATING INFLAMMATORY BOWEL DISEASE
May 29, 2019
INNOVATION PHARMACEUTICALS TO ATTEND 2019 BIO INTERNATIONAL CONVENTION, JUNE 3-6
May 21, 2019
INNOVATION PHARMACEUTICALS AT DIGESTIVE DISEASE WEEK CONFERENCE
May 16, 2019
INNOVATION PHARMACEUTICALS ANNOUNCES NON-BINDING TERM SHEET SIGNED WITH GLOBAL PHARMACEUTICAL COMPANY TO DEVELOP AND COMMERCIALIZE BRILACIDIN FOR ULCERATIVE PROCTITIS/PROCTOSIGMOIDITIS
May 1, 2019
INNOVATION PHARMACEUTICALS RECEIVES FDA END-OF-PHASE 2 MEETING MINUTES
April 23, 2019
INNOVATION PHARMACEUTICALS - JAMA ARTICLE REINFORCES NEED FOR NOVEL ORAL MUCOSITIS TREATMENTS IN SUPPORTIVE CANCER CARE
April 16, 2019
INNOVATION PHARMACEUTICALS REPORTS P53 DRUG CANDIDATE THERAPEUTIC POTENTIAL FURTHER SUPPORTED BY ACADEMIC RESEARCH IN LEUKEMIAS AND IN COMBINATION WITH CANCER IMMUNOTHERAPIES
April 9, 2019
INNOVATION PHARMACEUTICALS REPORTS ENHANCEMENTS IN MANUFACTURE OF BRILACIDIN PHASE 3 DRUG SUPPLY
March 28, 2019
INNOVATION PHARMACEUTICALS EUROPEAN SUBSIDIARY, IPIX PHARMA LTD., GRANTED MEETING WITH EUROPEAN MEDICINES AGENCY (EMA) TO DISCUSS INTERNATIONAL PHASE 3 BRILACIDIN ORAL MUCOSITIS PROGRAM
March 14, 2019
INNOVATION PHARMACEUTICALS REQUESTING EUROPEAN MEDICINES AGENCY (EMA) INPUT FOR INTERNATIONAL PHASE 3 BRILACIDIN ORAL MUCOSITIS PROGRAM
February 26, 2019
INNOVATION PHARMACEUTICALS FORMS IRISH SUBSIDIARY TO FACILITATE INTERNATIONAL DEVELOPMENT OF CLINICAL PIPELINE
February 19, 2019
INNOVATION PHARMACEUTICALS RECEIVES NEW PATENT FOR COMPOUNDS FOR USE IN TREATMENT OF ORAL MUCOSITIS
February 11, 2019
INNOVATION PHARMACEUTICALS FILES FORM 10-Q QUARTERLY REPORT
January 31, 2019
INNOVATION PHARMACEUTICALS ESTABLISHING EUROPEAN SUBSIDIARY; CEO INCREASES EQUITY STAKE IN IPIX
January 22, 2019
INNOVATION PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT PLANS FOR ORAL BRILACIDIN FOR INFLAMMATORY BOWEL DISEASE
January 14, 2019
INNOVATION PHARMACEUTICALS COMPLETES GASTRIC FLUID TESTING OF BRILACIDIN SUPPORTING DEVELOPMENT OF AN ORAL DOSAGE FORM TO TREAT INFLAMMATORY BOWEL DISEASE
January 8, 2019
PUBLISHED STUDIES CONFIRM CISPLATIN REMAINS PREFERRED CHEMOTHERAPY COMPONENT IN HEAD AND NECK CANCER TREATMENT
January 2, 2019
INNOVATION PHARMACEUTICALS RECEIVES NEW BRILACIDIN PATENT, FURTHER EXPANDING INTELLECTUAL PROPERTY ESTATE
http://www.ipharminc.com/press-release
4kids
Quote:
What is the normal protocol regarding PRs once a major deal is signed - does the BP make the first announcement, does the BP and the startup make joint announcements at the same time, or does the startup make the announcement?
For those that love baseball, the Atlantic League (minor league associated w/ Professional baseball) will test this summer a new rule where the runner can elect to "steal" first base on ANY pitch not caught by the catcher, not just after the 3rd strike as is now the rule. I realize they are trying to make baseball more exciting (as in using juiced baseball for more homers), but this possible new rule must have ol' Honus and Babe rolling in their graves.
6
